Description
Alunbrig, known generically as Brigatinib, is a type of medicine used to treat a form of lung cancer called non-small cell lung cancer (NSCLC). This treatment is indicated for adults whose cancer has a specific genetic change related to a gene known as ALK. Alunbrig works by blocking certain proteins in the body that help cancer cells grow and spread. By doing this, it can slow down or stop the cancer from getting worse.
Directions
Alunbrig is typically taken orally in pill form. The usual starting dosage is 90 mg once daily for the first 7 days. After this, the dosage generally increases to 180 mg once daily. Patients typically continue taking the medication until disease progression or they experience unacceptable toxicity. If a dose is missed, it's important to take it as soon as remembered unless it's close to the time for the next dose. In such cases, the missed dose should simply be skipped.
Ingredients
Alunbrig contains the active ingredient Brigatinib.
Contraindications
There are no contraindications listed on the drug label. However, avoid taking or using this medication if you have a known hypersensitivity to Brigatinib or any of its components.
Cautions
- Before starting treatment with Alunbrig, be sure to inform your healthcare provider about the following:
- Any medical conditions you currently have
- Any allergies
- All medications you are currently taking
- Whether you are pregnant or breastfeeding
- Severe or fatal lung reactions, including ILD or pneumonitis, have occurred. Most cases appear within the first few weeks of treatment. If new or worsening respiratory symptoms occur, treatment should be stopped and the patient evaluated.
- High blood pressure is common with Alunbrig. It is important to monitor blood pressure regularly. If severe hypertension occurs, Alunbrig may need to be temporarily stopped or the dose reduced.
- Alunbrig can cause slow heart rate (bradycardia). If symptoms like dizziness or chest discomfort occur, the medication may need to be paused, and heart rate should be monitored regularly.
- Vision changes such as blurred vision, photophobia, or reduced visual acuity can occur. Patients should report any new vision symptoms, and an eye exam may be necessary. Treatment may need to be adjusted based on severity.
- Muscle pain and CPK elevation are common side effects. Monitor CPK levels regularly, and adjust treatment if high levels occur.
- Alunbrig can cause elevated pancreatic enzymes, which may require dose reduction or temporary treatment interruption if severe.
- Liver damage can occur, and regular monitoring of liver function is recommended. If severe liver issues develop, treatment may need to be stopped.
- Elevated blood sugar levels are common with Alunbrig. Blood sugar should be monitored regularly, and diabetes management may be needed.
- Alunbrig can increase sensitivity to sunlight, so patients should take protective measures, including wearing sunscreen and protective clothing.
- Alunbrig can harm a fetus. Women of reproductive potential should use contraception during treatment and for 4 months afterward, and men should use contraception for 3 months after the last dose.
Side Effects
Alunbrig can cause several common side effects, including diarrhea, nausea, fatigue, vomiting, and muscle pain. Other common issues include headaches, high blood pressure, difficulty breathing, and skin rashes. While these side effects are typically mild, it's important to inform your healthcare provider if they persist or worsen over time.
Alunbrig can cause serious side effects such as lung inflammation, which may be life-threatening. Symptoms like chest pain, shortness of breath, or a persistent cough require immediate medical attention. Additionally, Alunbrig may cause high blood pressure, slow heart rate, and vision problems. If you experience dizziness, blurred vision, or unusual muscle pain, contact your doctor right away. Regular blood tests will help monitor your condition throughout treatment to manage these risks.
References
- Alunbrig (Brigatinib) Product Monograph. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2022.
- Alunbrig (Brigatinib) Drug Label Information. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2023.
About Dr. Gerardo Sison (Page Author)
Dr. Sison graduated with honors from the University of Florida. He began his career in pharmacy counseling patients in a community setting and later served in hospitals and clinics. He has also worked in medication therapy management services. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14466